Professor Mohammed Rudwan Arafah discusses the magnitude of cardiovascular disease in patients with Type 2 diabetes and elaborates on the evolution of CV evidence in mitigating these risks safely and effectively. Further, an overview of the cardiovascular outcomes trials (CVOT) of glucose lowering drugs is given, with specific focus on the recent evidence for primary prevention through the once weekly GLP1-RA dulaglutide. Prof. Arafah is a Professor of Medicine and Cardiology and Deputy Director of King Fahad Cardiac Center (Riyadh, Saudi Arabia).
An interactive question and answer session and discussion, moderated by Dr. Freek Bester will follow the talk.
Despite improved Heart Failure treatment with medical therapy and device implantation, the prognosis of patients with HFrEF has remained poor. Studies in high-income countries show that 20 % of patients die within 1 year of diagnosis, while one-year mortality for patients with HFrEF in Africa is reported to be 34 %. These figures highlight the need for new and improved treatments for HFrEF.
Professor Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis. Professor Verma will be discussing the evolving landscapes of SGLT2-Inhibitors in managing HFrEF patients with or without T2DM. There is an unmet need for early intervention and management of people living with heart failure. Professor Verma will discuss the new therapies that are available in order to effectively manage these patients thereby ensuring that they live longer, far less burdened by the devastation of their disease.
Pulmonary arterial hypertension (PAH) is a devastating disease characterised by progressive pulmonary vascular remodelling leading to increased right ventricular (RV) afterload, Right Ventricular failure and, if untreated, early death. Patients with PAH are often diagnosed late in the course of the disease when the pathologic changes are advanced and irreversible. Diagnosis of PAH, at this stage, is associated with poor prognosis for survival, underscoring the importance of early disease recognition and treatment.
Dr. Hani Sabbour, Consultant Cardiologist in the Heart and Vascular Institute at Cleveland Clinic Abu Dhabi, an expert in PAH, will take us through the importance of early diagnosis of PH and PAH with a focus on correct interpretation of the diagnostic investigations and cardiac imaging. In addition, Dr Sabbour will explore the latest pharmacological therapies available for PH patients and the significance of upfront dual therapy on diagnosis.
Dr van Wyk will present on how calcified lesions are not a homogenous entity and depending on the nature and severity of calcification effective treatment for patients with severe coronary calcification remains a challenge.
Calcified coronary lesions are associated with a higher incidence MACE, non-Q-wave MI, vessel dissection during PCI, un-dilatable lesions, balloon rupture, failure to deliver a stent, asymmetric stent expansion, restenosis, and target lesion revascularization (TLR).
Shockwave Coronary IVL incorporates a unique mechanism of action using sonic waves that disrupts both intimal and deep calcium in coronary lesions without damaging the soft tissue of the vessel wall or creating clinically meaningful embolic debris. The system is designed to address the challenges associated with coronary calcium as well as the limitations of existing therapies.